Allergies & Asthma

Asthma patients with confirmed COVID-19 were no more likely to require hospitalization or mechanical ventilation than patients without asthma, researchers found. Moreover, the asthma patients were less likely to die from COVID, reported Lacey Robinson, MD, of Massachusetts General Hospital in Boston, at the virtual annual meeting of the American Academy of Allergy, Asthma &
0 Comments
Managing your allergies is a big job – and can be a lifesaving practice. Like anything these days, there’s technology that can help make it simpler. In this blog, we’re talking about free apps that can help with adherence to your allergy treatment and medications, as well as food and environmental allergy management. Adherence apps
0 Comments
Inhaled budesonide (Pulmicort), a steroid generally used to treat asthma, dramatically reduced the need for hospitalization in COVID-19 patients within a week of symptom onset, a small randomized trial in the U.K. found. Among 139 patients with mild COVID-19 symptoms, 10 in the control group required either a COVID-19-related urgent care or emergency department (ED)
0 Comments
Most people look forward to spring, the warmer temperatures, and the increased sunshine it brings. What’s not to love? Millions of Americans may respond with “the allergies that come along with it.” The big offenders in the early spring are trees and mold, but grasses can start causing symptoms shortly after. To avoid the wrath
0 Comments
This story was originally published on Jan. 31, 2020. As part of MedPage Today‘s review of the past year’s top stories, we are republishing it, along with an update on peanut allergy therapies and related developments as the year went on. WASHINGTON — Aimmune Therapeutics’ oral immunotherapy for peanut allergy gained FDA approval late Friday,
0 Comments
Barbecue can return to the menu for individuals with “alpha-gal” syndrome — severe allergic reactions to the alpha-galactose saccharide found in red meat — with FDA approval Monday of pigs engineered to lack an enzyme considered key to the condition. Developed by a company called Revivicor, the “GalSafe” pigs might also have therapeutic potential as
0 Comments
New therapies and devices for chronic obstructive pulmonary disease (COPD) were approved in 2020 and researchers continued to explore expanding the definition of disease beyond spirometry. But 2020 was dominated by the struggles managing the care of highly vulnerable COPD patients during the COVID-19 pandemic. COVID Paradox The delivery of routine components of COPD care,
0 Comments
“While doctors have long believed that dementia presents in the checkbook, our study helps show that these financial symptoms are common and span years before and after diagnosis.” — Lauren Hersch Nicholas, PhD, MPP, of Johns Hopkins University in Baltimore, on research showing difficulties with finances were evident long before dementia diagnosis. “Hospitals, they want
0 Comments
New guidelines from the National Asthma Education and Prevention Program (NAEPP) of the National Heart, Lung, and Blood Institute (NHLBI) — the agency’s first update since 2007 — take account of new management options including single maintenance and reliever therapy (SMART) and long-acting muscarinic antagonists (LAMAs). As has long been standard practice, the foundation for
0 Comments
Note that some links may require registration or subscription. Pfizer and BioNTech announced emergency authorization from the United Kingdom for their COVID-19 vaccine on Wednesday. Meanwhile, White House Chief of Staff Mark Meadows invited FDA Commissioner Stephen Hahn, MD, to come explain why his agency hasn’t yet granted an emergency use authorization (EUA) for Pfizer’s
0 Comments
Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported. In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome
0 Comments